At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 95 enrolled
Drug / intervention
donanemab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments
In Brief
A Phase 2 clinical trial evaluating No Intervention and donanemab for Alzheimer Disease and 4 related conditions. Completed, enrolled 95 participants across 27 sites in 2 countries.
Detailed Summary
The main goals of this study are to further determine whether the study drug donanemab is safe and effective in participants with Alzheimer's disease and to validate neuropsychological assessments administered over videoconferencing
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Cognitive Impairment
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartNov 2020
Primary CompletionFeb 2024
TodayJul 2026
First PostedNov 23, 2020
Enrollment StartNov 23, 2020
Primary CompletionFeb 27, 2024
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 5.6 years ago
Interventions
No Interventionother
No intervention
donanemabdrug
Administered IV